What Researchers Did
Researchers conducted a review of current treatment options for Lyme borreliosis.
What They Found
Prompt oral antimicrobial therapy, such as doxycycline or amoxicillin, successfully treats over 90% of patients with Lyme borreliosis. For severe or chronic infections, parenteral ceftriaxone is the preferred drug due to its good central nervous system penetration and high efficacy. However, a small minority of patients, less than 10%, do not respond to treatment.
What This Means for Canadian Patients
Canadian patients diagnosed with Lyme borreliosis can expect high success rates with prompt oral antibiotic treatment. For more severe cases, intravenous ceftriaxone offers an effective option to manage the infection.
Canadian Relevance
This review does not have a direct Canadian connection.
Study Limitations
As a review, this study is limited by its reliance on existing literature and the absence of clinical trial data for several adjunct therapies.